Spravato vs. IV Ketamine in Manhattan: a NYC depression treatment comparison
Navigating depression treatment comparison in NYC
Finding the right care path involves weighing the rapid, customizable nature of IV infusions against the insurance-supported structure of Spravato.
We understand the unique pressures of the “Manhattan pace,” where you likely balance high performance with limited time, making the search for effective mental health solutions feel even more urgent. In a city that never sleeps, living with treatment-resistant depression (TRD) or severe anxiety can feel isolating. The urgency to return to one’s baseline of functionality—and beyond, to a state of flourishing—is a common sentiment among the members we treat. However, rushing into a treatment decision without understanding the nuances of the available modalities can lead to frustration.
We recognize the challenge of decision fatigue, especially when you are navigating treatment-resistant depression; conflicting advice about which modality is “best” can be overwhelming. Often, individuals seeking care are presented with binary choices that don’t account for their specific lifestyle constraints, financial situations, or physiological needs. This can lead to a “trial and error” approach that wastes valuable time. It is crucial to understand the definitions early: IV ketamine is a racemic mixture of the medicine administered directly into the bloodstream, while Spravato (esketamine) is an FDA-approved nasal spray formulation.
At Nushama, we believe in a hybrid model that removes the pressure to fit into a single box, allowing us to recommend a treatment plan based on your medical fit rather than inventory limitations. By offering both options, we eliminate the bias that often exists in single-modality clinics. Because we provide access to the full spectrum of ketamine therapies, our clinical team can objectively assess which route of administration aligns best with your goals.
Our goal is to guide you through this process with unbiased advice, ensuring your path to relief prioritizes your lifestyle, your safety, and your specific clinical needs. Whether you require the deep, immersive experience of an infusion to interrupt a severe depressive episode or the sustained, insurance-covered support of Spravato maintenance, the choice is made in partnership with you. We view you not just as a member of our clinic, but as a partner in a community dedicated to restoring mental wellness through evidence-based, compassionate care.
Understanding the medical difference: IV ketamine vs. Spravato
IV ketamine delivers a racemic mixture directly into the bloodstream for complete bioavailability, whereas Spravato is an FDA-approved nasal spray using only the S-enantiomer.
We explain to our members that IV ketamine is a racemic compound—containing both R- and S-molecules—that offers 100% bioavailability . This allows for precise uptake by your body without losing potency during digestion or absorption. This route of administration gives our medical team total control over the dosage. Because the medicine enters the bloodstream immediately, we can adjust the flow rate in real-time. If a session becomes too intense, we can dial it back instantly; if a member is not reaching the desired therapeutic effect, we can safely increase the dose. This level of precision is the gold standard for immediate crisis intervention and deep therapeutic exploration.
In contrast, we describe Spravato (esketamine) as a nasal spray formulation derived specifically from the S-enantiomer of ketamine, which interacts with NMDA receptors differently than the full molecule. Spravato comes in fixed doses (typically 56mg or 84mg), and once administered, the dose cannot be retracted or increased during that session. While highly effective, the nasal spray route lacks the minute-by-minute titration capability of IV therapy.
It is important to note the regulatory landscape: as of January 2025, the FDA has expanded approval for Spravato as a monotherapy, meaning it is no longer required to be taken alongside an oral antidepressant. This regulatory shift has increased access for many people who previously hesitated to engage with Spravato because they did not wish to start or continue daily oral SSRIs or SNRIs. This evolution in clinical protocols reflects a growing recognition of ketamine-based therapies as standalone treatments for specific conditions.
We often discuss neuroplasticity— the brain’s ability to reorganize itself by forming new neural connections—and how both treatments aim to catalyze this process to help you break free from rigid depressive patterns. Depression often operates like a well-worn ski track in the snow; it becomes difficult to steer out of the groove of negative rumination. Both IV ketamine and Spravato work to disrupt these rigid networks. The medicine is the catalyst, but the integration—the process of reviewing and applying insights from the session—is how you ensure those changes last.
The decision matrix: speed of relief vs. insurance-covered ketamine
IV ketamine prioritizes immediate symptom reduction, whereas Spravato leverages health insurance benefits to make ongoing care more affordable.
We find that for members in acute distress, the speed advantage of IV infusions is often the deciding factor, as it can provide symptom relief after just one or two sessions. When a person is navigating severe burnout, suicidal ideation, or treatment-resistant depression that impacts their ability to function daily, time is the most critical asset. For many Manhattan professionals, the higher upfront cost of IV therapy is viewed as an investment in rapid recovery, allowing them to return to their personal and professional lives sooner.
We can help you navigate the financial landscape, noting that Spravato is covered by many major plans like Oxford, UnitedHealthcare, Cigna, and Aetna, which can significantly reduce your out-of-pocket costs. For long-term maintenance or for those where cost is a primary barrier to entry, Spravato is an excellent option. Our care coordination team works diligently to verify benefits and handle prior authorizations, ensuring that you have a clear picture of the financial commitment before starting treatment. This accessibility makes Spravato a sustainable option for months-long treatment protocols.
We encourage you to view this choice as a balance between the upfront investment of IV for potentially faster results versus the longer-term, insurance-subsidized path of Spravato. There is no universally “correct” choice, only the choice that fits your current reality. Some members begin with a course of IV infusions to achieve rapid stabilization and then transition to Spravato for insurance-covered maintenance–, a strategy only possible in a clinic that supports both modalities.
The ‘Manhattan pace’: required time commitments for each treatment
Spravato requires a strict two-hour observation window after administration, resulting in a significantly longer clinic visit compared to the predictable duration of IV ketamine.
We adhere to the FDA protocol for Spravato, which includes monitoring you for at least two hours post-dose to ensure safety regarding sedation and blood pressure changes. This observation period is a standard safety protocol. During this time, you remain in our clinic under the supervision of our medical team. For busy New Yorkers, this block of time must be factored into the weekly schedule carefully, as the sedative effects of the medication typically make working or holding conference calls during this period impossible.
Conversely, our IV ketamine appointments typically involve a 40-minute active infusion followed by a recovery period, often allowing you to depart our Manhattan center within 90 minutes. Because the IV drip stops delivering medication the moment the infusion ends, the effects dissipate relatively quickly compared to the nasal spray, which continues to be absorbed. This efficiency appeals to those who need to fit treatment into a tight window. While you still cannot drive or return to high-stakes work immediately after an IV session, the total time “offline” is generally shorter.
We help you plan for the logistical impact, as you cannot work or check emails during the Spravato observation period due to sedative effects, effectively requiring you to block out a half-day in NYC. We advise members to treat this time as a protected space for rest and introspection rather than an inconvenience. However, for those whose schedules simply cannot accommodate a 2.5 to 3-hour door-to-door commitment twice a week, IV therapy may be the more viable logistical option.
Why unbiased care matters: avoiding the single-option trap
Personalized medicine relies on clinicians who can assess individual needs against multiple options rather than recommending a treatment based on inventory limitations.
We caution against the potential bias in single-modality clinics, where a provider might suggest Spravato simply because they lack the infusion equipment or medical staff required for IV therapy. Similarly, some IV-only clinics may dismiss Spravato because they do not wish to navigate the complexities of insurance reimbursement. In either scenario, the member is the one who loses out on true choice. At Nushama, our “agnostic” approach means we are not financially or operationally beholden to one specific treatment path.
We are proud to offer both options , ensuring that the treatment recommendation we make is driven strictly by your diagnosis, medical history, and personal goals. If your insurance covers Spravato and you have the time, we will happily facilitate that path. If you need immediate relief and require the precision of IV, we will guide you there. We also support the “hybrid” approach, where members might start with IV for the induction phase and transition to Spravato for maintenance, blending the clinical benefits of both.
We believe that regardless of the medication chosen, the “set and setting” are critical; a calm, supportive environment enhances the therapeutic potential of the medicine. Clinical studies consistently show that the environment in which psychedelic therapies are administered influences the outcome. Our center is designed to feel like a sanctuary, far removed from the sterile, fluorescent-lit atmosphere of a typical doctor’s office.
Frequently asked questions
Members often ask us about coverage specifics, the timeline for symptom relief, and the ability to switch between modalities.
Q: Does insurance cover IV ketamine in NYC?
A: We generally explain that IV ketamine is an out-of-pocket expense because most insurance carriers consider it “off-label” for mental health, whereas Spravato is widely covered by many insurance providers including Aetna, Cigna, Oxford, and UnitedHealthcare.
Q: Can I switch from Spravato to IV ketamine?
A: Yes, we frequently support members in transitioning between treatments if their initial choice does not yield the expected results—a process made seamless within our hybrid clinic where we maintain continuity of care regardless of the modality you choose.
Q: What is dissociation?
A: We define dissociation as a temporary feeling of being detached from your body or surroundings; this is a common, short-term effect of ketamine treatments that we monitor closely to ensure you feel safe and supported throughout the experience.
Q: What is integration?
A: We view integration as the essential process of reviewing and making sense of the insights gained during your treatment session so you can apply them to your daily life, transforming a fleeting experience into lasting behavioral change.
Q: Which treatment works faster?
A: Clinical evidence suggests that IV ketamine often offers more rapid symptom reduction, often noticeable earlier in the treatment protocol compared to nasal spray, making it the preferred choice for urgent distress.
Ready to find the path that fits your life? Speak with our team to find your path and explore which option is right for you.
